RxDoctor Payments DataLook up a doctor →

Nazanine Khairkhah, MD

Nephrology · Greenwich, CTNPI 1518937622

Payments from drug & device makers

$20,318in general payments, 2019–2025

Across 1,033 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • AstraZeneca$3K
  • Arbor Pharmaceuticals, Inc.$2K
  • Mallinckrodt Hospital Products Inc.$1K
  • Pfizer$1K
  • Amgen$898
  • plus $9K from 50 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)194$3,598
AstraZeneca(2 entities)128$2,911
Arbor Pharmaceuticals, Inc.100$1,745
Mallinckrodt Hospital Products Inc.52$1,192
Pfizer61$1,130
Amgen(2 entities)39$898
Novo Nordisk38$747
Takeda Pharmaceuticals U.S.A., Inc.43$709
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC42$673
OPKO Pharmaceuticals, LLC30$615
Kowa Pharmaceuticals America, Inc.37$552
Boehringer Ingelheim22$500
Exact Sciences20$493
ANI Pharmaceuticals, Inc.20$468
Axsome Therapeutics, Inc.23$443
Amarin Pharma, Inc.20$427
Otsuka America Pharmaceutical, Inc.20$410
Merck18$340
Travere Therapeutics, Inc.12$214
Eisai Inc.11$211
Currax Pharmaceuticals LLC13$194
Biohaven Pharmaceutical Holding Company Ltd.7$141
Bayer7$135
Abbott7$134
Lilly USA, LLC7$129
Biomerieux Inc1$106
Ironwood Pharmaceuticals, Inc5$100
Novartis4$89
Phathom Pharmaceuticals, Inc.3$72
IBSA Pharma Inc.4$70
Vifor Pharma, Inc.4$66
Teva Pharmaceuticals USA, Inc.3$62
Acella Pharmaceuticals, LLC3$59
Fresenius USA Marketing, Inc.3$57
Genentech USA, Inc.3$56
Kyowa Kirin, Inc.2$46
Calliditas Therapeutics US Inc.2$44
Esperion Therapeutics, Inc.2$43
Avion Pharmaceuticals3$42
Sanofi2$41
Azurity Pharmaceuticals, Inc.2$38
Ardelyx, Inc.2$38
Medicure Pharma Inc.1$36
Smith+Nephew1$25
Hikma Pharmaceuticals USA1$24
Astellas Pharma US Inc1$23
Vivus LLC1$23
Biohaven Pharmaceuticals, Inc.1$19
Akebia Therapeutics Inc1$19
Assertio Therapeutics, Inc.1$19
Scpharmaceuticals Inc.1$18
GSK1$16
Ultragenyx Pharmaceutical Inc.1$16
Nalpropion Pharmaceuticals LLC1$15
Seqirus USA Inc1$15
Sanofi Pasteur Inc.1$14

How this compares

$20,318 in reported general payments places this provider in the 85th percentile of 144 nephrology providers in Connecticut.

See all nephrology providers in Connecticut →

Medicare billing

Part B allowed, 2024
$273,993
Medicare patients
394
Services billed
3,371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in Greenwich

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →